LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Karyopharm Therapeutics Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERKPTI
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / KPTI COVERAGE

What’s moving Karyopharm Therapeutics Inc. now

Current reporting with the operating signal separated from the noise.

01
StocksToTrade

Karyopharm Therapeutics Inc. (KPTI) Stock Price | Live Quotes & Charts | NASDAQ

Investors are testing whether Karyopharm Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
TradingKey

KPTI|Karyopharm Therapeutics Inc|Price:1.920|Chg%:-5.090

The story matters when it changes Karyopharm Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
TradingKey

Karyopharm Therapeutics Inc (KPTI) Valuation: PE, PB & Fair Value Analysis

The development tests whether Karyopharm Therapeutics Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
04
Karyopharm Therapeutics Inc 25K0

Karyopharm Therapeutics Inc 25K0

The story matters when it changes Karyopharm Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Karyopharm Therapeutics Inc.: Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Karyopharm Therapeutics Inc.: Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

The story matters when it changes Karyopharm Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

The development tests whether Karyopharm Therapeutics Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
07
TipRanks

Karyopharm Therapeutics INC (KPTI) Q1 2026 Earnings Report - Results, Call & Slides

Investors are testing whether Karyopharm Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
08
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript

The story matters when it changes Karyopharm Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
09
Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

The story matters when it changes Karyopharm Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
10
Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings

Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings

Investors are testing whether Karyopharm Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
11
Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?

Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?

Investors are testing whether Karyopharm Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
12
Karyopharm Therapeutics Inc. (KPTI) Q2 2023 Earnings Call Transcript

Karyopharm Therapeutics Inc. (KPTI) Q2 2023 Earnings Call Transcript

Investors are testing whether Karyopharm Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest KPTI filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-14 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-03 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-13 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-31 · Period 2026-07-30SEC ↗8-KMaterial company eventFiled 2026-07-17 · Period 2026-07-13SEC ↗8-KMaterial company eventFiled 2026-05-28 · Period 2026-05-21SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-13 · Period 2026-04-13SEC ↗4Official SEC filingFiled 2026-07-30 · Period 2026-07-28SEC ↗
EARNINGS / QUARTERLY TRACKER

Karyopharm Therapeutics Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.